<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-135573" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Compare and Contrast the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Latif</surname>
            <given-names>Wafa</given-names>
          </name>
          <aff>Florida Atlantic University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lambrinos</surname>
            <given-names>Katerina J.</given-names>
          </name>
          <aff>University of Florida College of Pharmacy, Gainesville, FL</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rodriguez</surname>
            <given-names>Rolando</given-names>
          </name>
          <aff>Baptist Health Boca Raton Regional Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Wafa Latif declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Katerina Lambrinos declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rolando Rodriguez declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-135573.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">Glucagon-like peptide-1 receptor agonists (GLP-1RA, GLP-1DAs, incretin mimetics, or GLP-1 analogs) are a class of medications utilized in treating type 2 diabetes and obesity. Clinical trials show the superiority of GLP-1RA to other antihyperglycemic drugs in improving glycemic efficacy, reducing weight and blood pressure, and having a cardioprotective effect, all without the risk of hypoglycemia. These drugs have transformed the guidelines for the management of diabetes.</p>
        <p>
<bold>FDA-approved GLP-1 receptor agonists for glycemic control include:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dulaglutide (subcutaneous-SC)</p>
          </list-item>
          <list-item>
            <p>Exenatide injectable solution&#x000a0;subcutaneous</p>
          </list-item>
          <list-item>
            <p>Exenatide injectable suspension SC</p>
          </list-item>
          <list-item>
            <p>Liraglutide SC</p>
          </list-item>
          <list-item>
            <p>Liraglutide/insulin&#x000a0;degludec&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Lixisenatide/insulin glargine</p>
          </list-item>
          <list-item>
            <p>Semaglutide (oral, SC)</p>
          </list-item>
          <list-item>
            <p>Tirzepatide (dual GIP/GLP-1 receptor agonist)</p>
          </list-item>
        </list>
        <p>
<bold>FDA-approved GLP-1 agonists for weight loss include:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Semaglutide SC</p>
          </list-item>
          <list-item>
            <p>Liraglutide SC&#x000a0;<xref ref-type="bibr" rid="article-135573.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>The FDA approved the first GLP-1RA exenatide in 2005. The oral semaglutide tablet was approved by the FDA in 2019. Except for oral semaglutide, all the other drugs are subcutaneous injections. Albiglutide was discontinued in 2017 due to a decrease in sales.<xref ref-type="bibr" rid="article-135573.r2">[2]</xref><bold>&#x000a0;</bold>Similarly, lixisenatide has been recently withdrawn from the US market, a decision driven by commercial considerations rather than safety or efficacy concerns.&#x000a0;According to ADA, the combination of basal insulin and GLP-1RA demonstrates potent glucose-lowering effects while minimizing weight gain and reducing the risk of hypoglycemia compared to intensified insulin regimens. Currently,&#x000a0;2 distinct once-daily, pre-mixed dual-combination products are available, which include lixisenatide&#x000a0;with insulin glargine and&#x000a0;liraglutide with insulin degludec.<xref ref-type="bibr" rid="article-135573.r3">[3]</xref></p>
        <p>The FDA approves all GLP-1RA to improve glycemic control in patients with type 2 diabetes as an adjunct to diet and exercise.&#x000a0;The American Diabetes Association guidelines state metformin is the initial first-line therapy for patients diagnosed with type 2 diabetes. If a patient is intolerant to metformin or&#x000a0;metformin is contraindicated, a GLP-1RA should be introduced as part of their medication regimen. The addition of a GLP-1 analog should also be considered in those patients who cannot reach their glycemic goal with other antidiabetic medications or if their HbA1c is &#x02265;1.5% above their target.</p>
        <p>The FDA did not approve of using GLP-1RA for patients with type 1 diabetes. However, the ADA's 2023 guidelines acknowledge the potential off-label application of GLP-1RAs in treating T1DM. Notably, extensive clinical trials, primarily utilizing liraglutide at a daily dosage of 1.8 mg, have shown modest decreases in HbA1c levels of approximately 0.4%. Furthermore, patients in these trials had significantly reduced body weight by around 5 kg and had lowered insulin requirements.<xref ref-type="bibr" rid="article-135573.r4">[4]</xref></p>
        <p>Subcutaneous semaglutide is FDA-approved to reduce the risk of major cardiovascular (CV) adverse events in patients with type 2 diabetes and established cardiovascular disease. Dulaglutide is FDA-approved for improving HbA1c in patients with an increased risk of CV events.&#x000a0;Lixisenatide can be used in combination with long-acting insulin.&#x000a0;High-dose liraglutide has been FDA-approved for chronic weight management in patients aged 12 or older with a BMI of 30 or greater.&#x000a0;</p>
        <p>Semaglutide at 2.4 mg once-weekly injection has been studied for weight loss and is effective. The FDA has also approved this medication for chronic weight management as of 2021.<xref ref-type="bibr" rid="article-135573.r5">[5]</xref>&#x000a0;The other GLP-1 analogs also have the favorable side effect of weight loss, although, except for high-dose liraglutide and semaglutide, they have not been FDA-approved for this indication.&#x000a0;Of note, exenatide may be used off-label for the management of idiopathic intracranial hypertension.<xref ref-type="bibr" rid="article-135573.r6">[6]</xref></p>
      </sec>
      <sec id="article-135573.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Glucagon-like peptide-1 agonists (GLP-1RA) are analogs of GLP-1, a gut-derived peptide hormone that exhibits a glucose-lowering effect via stimulation of insulin secretion from pancreatic islets in response to an oral glucose load, known as the incretin effect. Unlike the natural peptide hormone, synthetic GLP-1 is resistant to degradation by the dipeptidyl peptidase 4 (DPP-4) enzyme, and thus it has a longer half-life. The GLP-1 activity in patients with type 2 diabetes may be decreased.&#x000a0;GLP-1 also slows gastric emptying, suppresses appetite, improves satiety, decreases inappropriate glucagon secretion, and promotes beta-cell proliferation.<xref ref-type="bibr" rid="article-135573.r7">[7]</xref>&#x000a0;GLP-1 receptor agonists have also demonstrated the ability to restore insulin secretory functions, thereby improving glycemic control and body weight reduction in diabetic patients.<xref ref-type="bibr" rid="article-135573.r8">[8]</xref>&#x000a0;</p>
        <p>The short-acting formulations work by delaying gastric emptying, thus reducing postprandial glucose levels. The long-acting agents affect both fasting and postprandial glucose levels.<xref ref-type="bibr" rid="article-135573.r9">[9]</xref>&#x000a0;Existing evidence suggests roles that GLP-1 analogs can play on receptors expressed throughout the human body, including reducing blood pressure, improving endothelial and myocardial function, recovering failing and ischemic heart, arterial vasodilation, and increased diuresis and natriuresis.<xref ref-type="bibr" rid="article-135573.r10">[10]</xref></p>
        <p>
<bold>Comparison of Different GLP-1 Agonists</bold>
</p>
        <p>Numerous clinical trials and studies have been conducted between the short-acting and long-acting GLP-1 analogs to gauge their efficacy, safety, and tolerability. In addition, the added benefit of weight loss and improved cardiovascular and renal outcomes was also assessed.<bold>Efficacy and adverse effects&#x000a0;</bold></p>
        <p>One meta-analysis showed that once-weekly GLP-1RA were more effective in reducing HbA1c levels and equally as effective in weight loss than exenatide twice-daily injection, but not better than liraglutide once-daily injection.<xref ref-type="bibr" rid="article-135573.r11">[11]</xref>&#x000a0;To further support this, a study showed that long-acting GLP-1RA like dulaglutide, liraglutide, and once-weekly exenatide were superior to exenatide twice daily and lixisenatide at lowering fasting plasma glucose levels and HbA1c levels of patients.<xref ref-type="bibr" rid="article-135573.r12">[12]</xref>&#x000a0;</p>
        <p>Another meta-analysis demonstrated that liraglutide decreased HbA1c more than exenatide, and there was no difference in HbA1c reduction between liraglutide and dulaglutide. The adverse effects were mainly gastrointestinal, with less nausea seen in exenatide once-weekly injection, and most adverse effects were seen with short-acting agents.<xref ref-type="bibr" rid="article-135573.r13">[13]</xref>&#x000a0;The LEAD-6 trial compared liraglutide 1.8mg once a day with exenatide 10 mcg twice a day, and it showed a greater HbA1c reduction and fewer adverse effects with liraglutide, including hypoglycemia.<xref ref-type="bibr" rid="article-135573.r14">[14]</xref>&#x000a0;In DURATION-6, liraglutide once daily was compared to exenatide once weekly, and liraglutide showed a significant reduction in both HbA1c and weight. However, more GI side effects were associated with using liraglutide.&#x000a0;Compared to exenatide once-weekly injection, exenatide twice-daily injection showed a greater reduction of HbA1c level; however, there were more injection site reactions.<xref ref-type="bibr" rid="article-135573.r15">[15]</xref>&#x000a0;</p>
        <p>In the AWARD-1 trial, dulaglutide was superior to exenatide twice-daily injection. Further trials followed this up, and in the AWARD 6 trial, once-weekly dulaglutide was shown to be as effective as once-weekly liraglutide. Liraglutide, however, had more significant weight loss potential.<xref ref-type="bibr" rid="article-135573.r16">[16]</xref>&#x000a0;In another trial, dulaglutide, when compared to liraglutide, had a greater HbA1c reduction.<xref ref-type="bibr" rid="article-135573.r17">[17]</xref>&#x000a0;When dulaglutide's&#x000a0;initiation in patients was compared to exenatide once weekly and liraglutide, dulaglutide had a higher adherence rate and lower discontinuation rates within 6 months.<xref ref-type="bibr" rid="article-135573.r18">[18]</xref>&#x000a0;A more recent randomized controlled trial called SUSTAIN-7 compared semaglutide once-weekly injection to dulaglutide at both low and high doses. Semaglutide showed superiority over dulaglutide in improving glycemic control and weight loss &#x0003e;5%, with both drugs having a similar safety profile.<xref ref-type="bibr" rid="article-135573.r19">[19]</xref>&#x000a0;</p>
        <p><bold>Cardiovascular outcomes</bold>Several cardiovascular outcome trials have been done on the&#x000a0;GLP-1RA. The LEADER-6 trial showed that liraglutide had a cardiovascular benefit in high-risk patients. The SUSTAIN 6 trial demonstrated a statistically significant reduction in death from cardiovascular events with the use of subcutaneous semaglutide; however, it also had the highest decrease in HbA1c, so it was unclear whether the reduction of death from CV events was from the medication or the improved glycemic control.&#x000a0;Out of the&#x000a0;7 trials, all have shown noninferiority, and liraglutide, subcutaneous semaglutide, and dulaglutide have significantly reduced cardiovascular outcomes.<xref ref-type="bibr" rid="article-135573.r20">[20]</xref>&#x000a0;According to a post hoc analysis of the SUSTAIN and PIONEER trials, semaglutide has shown a decreased relative risk and absolute risk reduction for major adverse cardiovascular events versus its comparators.<xref ref-type="bibr" rid="article-135573.r21">[21]</xref>&#x000a0;The AHA emphasizes reducing ASCVD-related outcomes like MI, stroke, and cardiovascular death and recommends GLP-1 receptor agonists such as liraglutide, subcutaneous semaglutide, dulaglutide, and albiglutide, which is currently not available in the US or EU, for their established cardiovascular benefits.<xref ref-type="bibr" rid="article-135573.r22">[22]</xref></p>
        <p>
<bold>Renal outcomes</bold>
</p>
        <p>GLP-1 agonists have demonstrated the most significant renal benefit, primarily by reducing new-onset severely increased albuminuria. The AWARD-7 trial comparing dulaglutide and insulin glargine was the only trial involving this class of medications to enroll patients with moderate-to-severe chronic kidney disease exclusively.&#x000a0;Patients concurrently on an ACE inhibitor or angiotensin receptor blocker who received dulaglutide experienced significantly less eGFR decline than those who received insulin glargine. For this reason, patients with an eGFR as low as 15 mL/min per 1.73 m<sup>2</sup> can safely be treated with dulaglutide per FDA labeling.<xref ref-type="bibr" rid="article-135573.r23">[23]</xref>&#x000a0;</p>
        <p>Injectable semaglutide in SUSTAIN-6 showed the most significant albuminuria reduction, followed by liraglutide and dulaglutide in their respective cardiovascular outcomes trials.&#x000a0;The trial included patients across the spectrum of renal dysfunction except for dialysis patients. PIONEER 6, which evaluated cardiovascular outcomes of oral semaglutide, did not assess the drug's effect on albuminuria or loss of eGFR.<xref ref-type="bibr" rid="article-135573.r24">[24]</xref>&#x000a0;</p>
        <p>
<bold>Weight loss</bold>
</p>
        <p>Recently, weekly semaglutide 2.4 mg became the first approved drug for chronic weight management in overweight adults or those with general obesity with at least one weight-related comorbidity since the approval of high-dose liraglutide in 2014. Compared to the SCALE trial comparing weight management in liraglutide versus placebo, the&#x000a0;4 randomized controlled trials comparing semaglutide to placebo showed a greater average weight loss, resulting in a more significant percentage of patients losing at least 5% of their body weight.</p>
        <p>
<bold>Adherence to therapy</bold>
</p>
        <p>The once-weekly injections were also compared based on patient compliance&#x000a0;and adherence. A retrospective observational study evaluated the adherence to dulaglutide versus liraglutide and exenatide once weekly. The patients taking dulaglutide were remarkably more persistent in taking the drug and adherent than those patients taking exenatide extended-release or liraglutide. Another observational study examined adherence between dulaglutide, semaglutide, and exenatide. At 6 months, more patients preferred to use dulaglutide than exenatide and semaglutide.<xref ref-type="bibr" rid="article-135573.r25">[25]</xref>&#x000a0;Although the GLP-1RA vary within their class, the efficacy and safety profile are comparable. Choosing which GLP-1RA to use will depend on patient preferences, the patient's comorbidities, reaction to adverse effects, convenience, and cost. Also, GLP-1 agonists (eg, exenatide) are under investigation and have shown promising results&#x000a0;in idiopathic intracranial hypertension.<xref ref-type="bibr" rid="article-135573.r6">[6]</xref></p>
        <p>
<bold>Clinical Pharmacokinetics</bold>
</p>
        <p>
<bold>Absorption</bold>
</p>
        <p>Exenatide, administered twice daily, achieves a peak concentration within 2.1&#x000a0;to 2.2 hours, with an elimination half-life ranging from 3.3 to 4.0 hours. Liraglutide, given once daily, exhibits a more prolonged duration to peak concentration, spanning 11 to 13.8 hours, and has a corresponding elimination half-life of 12.6&#x000a0;to 14.3 hours. Lixisenatide, also administered once daily, reaches peak levels at approximately 2 hours and has a relatively shorter half-life of 2.6 hours. Semaglutide, whether administered subcutaneously once weekly or orally once daily, showcases a more sustained duration of action. The subcutaneous form achieves peak concentration at 24 hours, with an impressively extended elimination half-life of 5.7&#x000a0;to 6.7 days. The oral formulation displays a shorter time to peak concentration, ranging from 1 to 4 hours, yet maintains a parallel elimination half-life of 5.7&#x000a0;to 6.7 days.<xref ref-type="bibr" rid="article-135573.r22">[22]</xref></p>
        <p>
<bold>Distribution</bold>
</p>
        <p>Liraglutide, approved in 2009, is designed to closely mimic the amino acid sequence of mammalian GLP-1. A free fatty acid side chain is attached to enhance its binding to albumin in plasma and interstitial fluid. Only a small fraction, estimated at 1% to 2%, of liraglutide circulates in a form free from albumin, enabling it to penetrate tissues and interact with receptors. The albumin-bound majority forms a reservoir, resulting in an extended duration of action. Liraglutide's elimination half-life is approximately 13 hours, making it well-suited for once-daily dosing. Exenatide is developed with the active ingredient slowly released from a time-releasing matrix after subcutaneous injection. Consequently, the onset of action is considerably delayed, requiring 8 to 10 weeks of treatment to reach a steady state. Other approaches involve conjugating modified GLP-1 to large proteins like an immunoglobulin Fc fragment (eg, dulaglutide) or albumin (eg, albiglutide).&#x000a0;</p>
        <p>Following subcutaneous injection, they achieve effective circulating levels quite early, initiating a reduction in plasma glucose shortly after initiating treatment. Semaglutide shares a structure largely similar to liraglutide, GLP-1, with a free fatty acid side chain but has a notably extended half-life, likely due to an even stronger binding affinity for albumin. Semaglutide is combined with sodium N-(8-[2-hydroxybenzoyl]amino) caprylate (SNAC) for oral delivery. To compensate for the relatively low bioavailability of semaglutide when absorbed through the gastrointestinal tract, oral semaglutide necessitates daily administration.&#x000a0;Glucagon-like peptide-1 receptor agonists generally do not cross the blood-brain barrier except liraglutide and semaglutide. This allows them to access specific brain regions, including circumventricular organs, arcuate nucleus, area postrema, nucleus tractus solitarius, and dorsal motor nucleus of the vagus nerve.&#x000a0;In areas where semaglutide is prominently absorbed, many GLP-1 receptors (GLP-1Rs) exist, particularly in the hypothalamus and rhombencephalon.</p>
        <p>Experimental findings in subjects deficient in GLP-1 receptors emphasize their crucial role in semaglutide absorption. GLP-1RAs, like semaglutide, stimulate POMC/CART neurons associated with appetite suppression and inhibit NPY/AgRP neurons linked to appetite stimulation in the hypothalamus. This effect mirrors that of liraglutide.&#x000a0;Upon interaction with GLP-1RAs, specific brain regions, such as the area postrema and nucleus tractus solitarius in the brain stem, are rapidly activated.&#x000a0;Additionally, GLP-1RAs induce activation in brain regions not directly accessible to them, contributing to appetite regulation and meal termination. These regions include the nuclei of the stria terminalis, central amygdala nucleus, dorsal thalamus, parasubthalamic nucleus, and parabrachial nucleus.<xref ref-type="bibr" rid="article-135573.r26">[26]</xref></p>
        <p>
<bold>Metabolism</bold>
</p>
        <p>The GLP-1 agonists are recombinant polypeptides and undergo minimal to no hepatic metabolism.<xref ref-type="bibr" rid="article-135573.r27">[27]</xref>&#x000a0;Albiglutide and dulaglutide are large recombinant fusion proteins metabolized via general protein catabolism pathways, not involving the cytochrome P450 enzymes. This is significant because the cytochrome P450 enzymes are often involved in drug-drug interactions. Exenatide is primarily eliminated by glomerular filtration with subsequent proteolytic degradation. Liraglutide alone or in combination with insulin degludec is metabolized&#x000a0;by DPP-4 and endogenous endopeptidases.<xref ref-type="bibr" rid="article-135573.r28">[28]</xref>&#x000a0;The lixisenatide/insulin glargine combination involves lixisenatide, which is degraded by peptidases, and insulin glargine, metabolized at the B chain's carboxyl terminus, forming&#x000a0;2 metabolites. Semaglutide undergoes metabolism into amino acids by serum and tissue proteases. Tirzepatide, a structurally modified polypeptide, undergoes metabolism into separate amino acids within various tissues and cell types, including the liver.<xref ref-type="bibr" rid="article-135573.r29">[29]</xref><xref ref-type="bibr" rid="article-135573.r30">[30]</xref><xref ref-type="bibr" rid="article-135573.r31">[31]</xref></p>
        <p>
<bold>Excretion</bold>
</p>
        <p>The kidneys primarily eliminate exenatide and lixisenatides. They are cleared from the systemic circulation by glomerular filtration with subsequent proteolytic degradation; use with caution in patients with CKD.<xref ref-type="bibr" rid="article-135573.r32">[32]</xref> Liraglutide, dulaglutide, albiglutide, and semaglutide are metabolized similarly to large proteins, primarily through general protein catabolism pathways, without a specific organ as the primary route of elimination.</p>
      </sec>
      <sec id="article-135573.s3" sec-type="Administration">
        <title>Administration</title>
        <p>GLP-1 receptor agonists are typically administered as follows: exenatide twice daily, exenatide extended-release (ER) once weekly, lixisenatide once daily, liraglutide once daily, dulaglutide once weekly, semaglutide once weekly, and oral semaglutide once daily.</p>
        <p>Initially, GLP-1RAs were manufactured as an injectable medication due to their poor oral bioavailability. The once-daily injections are liraglutide and lixisenatide, while dulaglutide and semaglutide are once weekly. Exenatide has a twice-daily formulation and an extended-release (ER) once-weekly injection formulation. In 2019, an oral semaglutide tablet became available in dosages of 3 mg, 7 mg, and 14 mg.<xref ref-type="bibr" rid="article-135573.r33">[33]</xref>&#x000a0;Patient preference is mainly for less frequent dosing regimens and oral formulations over injectable medication. Patient adherence also depended upon the type of device and needle size, showing a preference for narrower needles.<xref ref-type="bibr" rid="article-135573.r34">[34]</xref><xref ref-type="bibr" rid="article-135573.r35">[35]</xref><xref ref-type="bibr" rid="article-135573.r18">[18]</xref>&#x000a0;GLP-1 receptor agonists can now be used in combination with insulin. This regimen has a synergistic effect, with insulin lowering fasting blood glucose levels and GLP-1 analogs lowering postprandial glucose levels. There is also a reduced risk of hypoglycemia, and the GLP-1 RA use will offset the weight gain that may be caused by insulin use.<xref ref-type="bibr" rid="article-135573.r36">[36]</xref>&#x000a0;The injectable medication should be administered in the patient&#x02019;s thigh, abdomen, or upper arm. The patient should be instructed to change injection sites each time to reduce the risk of infection at the site.&#x000a0;</p>
        <p>Missed dose instructions vary among the once-weekly formulations. Exenatide extended-release and dulaglutide can be taken as soon as the patient remembers, as long as the next scheduled dose is at least&#x000a0;3 days later. Conversely, semaglutide can be taken within&#x000a0;5 days of the missed dose. If outside these parameters, the patient should be instructed to skip the dose entirely and continue with the next regularly scheduled dosing day.</p>
        <p>Short-acting exenatide and lixisenatide should be given within 60 minutes of meals, whereas all others can be administered without regard to meals.&#x000a0;The oral semaglutide tablet should be taken 30 minutes before any food, oral medication, or beverage, with 4 ounces of water. If taken with any other oral medication, it may alter the absorption of the oral semaglutide.<xref ref-type="bibr" rid="article-135573.r35">[35]</xref></p>
        <p>
<bold>Type 2 Diabetes</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Albiglutide</bold>: The starting dose is 30 mg once weekly, which may be increased to a maximum of 50 mg weekly.</p>
          </list-item>
          <list-item>
            <p><bold>Dulaglutide</bold>: The starting dose is 0.75 mg once weekly, which may increase to a maximum of 1.5 mg weekly.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Exenatide injectable solution (immediate-release)</bold>: The starting dose is 5 mcg subcutaneously twice daily for the first month, then 10 mcg subcutaneously twice daily.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Exenatide injectable suspension (extended-release)</bold>: 2 mg subcutaneously once weekly.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Liraglutide</bold>: The starting dose is 0.6 mg subcutaneously once daily for 1 week, then increase to 1.2 mg once daily. If necessary, after at least 1 week, the dose may be increased to a maximum of 1.8 mg once daily.</p>
          </list-item>
          <list-item>
            <p><bold>Liraglutide/insulin degludec</bold>: The starting dose is insulin degludec 10 units and liraglutide 0.36 mg subcutaneously once daily. The dose can be increased by 2 units every&#x000a0;3 to&#x000a0;4 days to a maximum of 50 units of insulin degludec and 1.8 mg of liraglutide daily.</p>
          </list-item>
          <list-item>
            <p><bold>Lixisenatide</bold>:&#x000a0;The starting dose is 10 mcg subcutaneously once daily for 14 days, then 20 mcg once daily.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Lixisenatide/insulin glargine</bold>: The starting dose is insulin glargine&#x000a0;15 units and lixisenatide 5 mcg subcutaneously once daily, which may be increased by 1 to 2 units every week up to a maximum of 60 units insulin glargine and 20 mcg lixisenatide once daily.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Semaglutide</bold>: The starting dose is 0.25 mg subcutaneously once weekly for 4 weeks, then increase to 0.5 mg weekly. If necessary, after at least 4 weeks, the dose may be increased to a maximum of 1 mg once weekly.</p>
          </list-item>
        </list>
        <p><bold>Weight Loss:&#x000a0;</bold>Liraglutide and semaglutide have received FDA approval for weight loss. Liraglutide is administered subcutaneously, commencing with an initial dose of 0.6 mg once daily for the first week. The dosage is then gradually escalated in increments of 0.6 mg, reaching a maximum of 3 mg once daily. Semaglutide is also administered subcutaneously, with an initial dosage of 0.25 mg once weekly for&#x000a0;4 weeks. Subsequently, the dose is increased incrementally every week, with a maximum dosage of 2.4 mg once weekly.<xref ref-type="bibr" rid="article-135573.r37">[37]</xref></p>
        <p>
<bold>Special Patient Populations</bold>
</p>
        <p><bold>Patients with hepatic impairment</bold>: Dosing in hepatic impairment is not defined for dulaglutide; therefore, caution is advised. Semaglutide and liraglutide require no dose adjustment for hepatic impairment.</p>
        <p><bold>Patients with renal impairment</bold>: According to the Kidney Disease Improving Global Outcomes (KDIGO) and the American Diabetes Association (ADA), no dose adjustment is necessary for dulaglutide, liraglutide, and semaglutide in cases of renal impairment. This makes them the preferred choice for patients with chronic kidney disease. In contrast, clinicians should exercise caution when initiating or increasing the dose of exenatide and avoid using the once-weekly formulation of exenatide in stage 3b chronic kidney disease (ie, estimated glomerular filtration rate 30&#x02013;44 mL/min/1.73 m&#x000b2;).<xref ref-type="bibr" rid="article-135573.r32">[32]</xref></p>
        <p><bold>Pregnant patients</bold>: Based on the current evidence, discontinuing GLP-1RAs during pregnancy is recommended. Maintaining a record of pregnancy outcomes in pharmacological databases is also suggested, as the available data on the subject is largely limited to animal studies and deemed insufficient.</p>
        <p><bold>Breastfeeding patients</bold>:&#x000a0;GLP-1 agonists are a class of medications used to manage type 2 diabetes. Limited data on the excretion of GLP-1 agonists in human breast milk is available. Therefore,&#x000a0;caution is recommended when considering GLP-1RA during lactation.&#x000a0;</p>
        <p><bold>Pediatric patients</bold>: Evidence supports high-dose liraglutide in pediatric patients for obesity. However, clinicians should still be vigilant about monitoring and dosage as more high-quality clinical studies are required to assess safety and tolerability.<xref ref-type="bibr" rid="article-135573.r38">[38]</xref>&#x000a0;The American Academy of Pediatrics (AAP) acknowledges that the FDA has approved the use of liraglutide for the long-term management of obesity, both with and without type 2 diabetes, in patients aged 12 years&#x000a0;or older.<xref ref-type="bibr" rid="article-135573.r39">[39]</xref></p>
        <p><bold>Older patients</bold>: Mate-analysis concluded that&#x000a0;in older adults with diabetes, GLP-1RAs reduced major adverse cardiovascular events.<xref ref-type="bibr" rid="article-135573.r40">[40]</xref></p>
      </sec>
      <sec id="article-135573.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Since GLP-1 receptor agonists mimic the action of a peptide produced in the GI tract, the most reported side effects are gastrointestinal (GI), including nausea, vomiting, and diarrhea. The GI side effects are dose-dependent, and increasing the dosage should be done slowly.<xref ref-type="bibr" rid="article-135573.r13">[13]</xref>&#x000a0;Patients should be educated that this drug slows gastric emptying, and there may be a feeling of early satiety. Nausea can occur if attempting to eat when already full. A 34-trial meta-analysis demonstrated that once-weekly exenatide had the lowest risk of vomiting when comparing the adverse effects.<xref ref-type="bibr" rid="article-135573.r12">[12]</xref></p>
        <p>Although classified as low risk, GLP-1RA can be associated with hypoglycemia with no clinically significant difference in incidence among the agents. The concomitant use of insulin or insulin secretagogues, such as sulfonylureas, potentiates this risk.<xref ref-type="bibr" rid="article-135573.r8">[8]</xref>&#x000a0;Injection site reactions and erythema have been reported to be more frequent with exenatide administered once weekly than twice daily. Injection site reactions are also more common, with exenatide taken once weekly compared to liraglutide taken once daily.&#x000a0;</p>
        <p>Exenatide also has the&#x000a0;adverse effect of increasing the INR in patients taking warfarin.&#x000a0;For semaglutide, rapid improvement of glycemic control has been associated with a temporary worsening of preexisting diabetic retinopathy. The effects of long-term glycemic control on diabetic retinopathy complications have not been studied.&#x000a0;In a trial for liraglutide, 3.1% of patients taking the medication versus 1.9% of patients on placebo reported an event of gallbladder disease. If cholelithiasis or cholecystitis is suspected, gallbladder studies and workup are indicated.&#x000a0;</p>
        <p>Antibody formation was rare in patients treated with once-weekly injectables, while a greater percentage of patients developed antibodies to twice-daily exenatide and once-daily lixisenatide. The antibodies produced caused a smaller decrease in HbA1c and reduced glycemic efficacy in patients taking exenatide and lixisenatide. When these patients were switched to liraglutide, their new regimen was unaffected by the antibodies.<xref ref-type="bibr" rid="article-135573.r8">[8]</xref>&#x000a0;</p>
        <p>Dulaglutide is associated with cardiovascular conduction abnormalities such as sinus tachycardia, PR interval prolongation, and 1st-degree AV block.&#x000a0;The drug should be used cautiously in patients with preexisting arrhythmia.<xref ref-type="bibr" rid="article-135573.r41">[41]</xref><xref ref-type="bibr" rid="article-135573.r42">[42]</xref>&#x000a0;In many phase III clinical trials, nasopharyngitis and upper respiratory infections (URIs) were reported. These symptoms were mostly noted in the PIONEER 9 and 10 trials. The mechanism of action of the URIs is unknown; however, its presence across trials qualifies it as an adverse effect to be studied further regarding GLP-1 receptor agonists.</p>
      </sec>
      <sec id="article-135573.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The following contraindications should be considered with&#x000a0;GLP-1RAs:</p>
        <list list-type="bullet">
          <list-item>
            <p>All GLP-1 receptor agonists are contraindicated in patients with hypersensitivity to the drug.<xref ref-type="bibr" rid="article-135573.r43">[43]</xref><xref ref-type="bibr" rid="article-135573.r44">[44]</xref></p>
          </list-item>
          <list-item>
            <p>There is an increased risk of fatal hemorrhagic and necrotizing pancreatitis using any GLP-1 analog. The mechanism of pancreatitis is currently unknown but has been demonstrated with postmarketing surveillance. GLP-1RAs should be discontinued if a patient has a history of pancreatitis or develops pancreatitis.<xref ref-type="bibr" rid="article-135573.r45">[45]</xref></p>
          </list-item>
          <list-item>
            <p>Semaglutide, dulaglutide, exenatide extended-release, liraglutide, and&#x000a0;tirzepatide are contraindicated in patients with a family history of medullary thyroid cancer or patients with multiple endocrine neoplasia syndrome type 2 (MEN2). Studies have shown that liraglutide causes C-cell hyperplasia and increases rodent calcitonin release. Further investigations on humans are necessary to make a more definitive statement.<xref ref-type="bibr" rid="article-135573.r46">[46]</xref><xref ref-type="bibr" rid="article-135573.r47">[47]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Exenatide should not be used in patients with end-stage renal disease or CrCl less than 30 mL/min. There are also reports of drug-induced thrombocytopenia with exenatide, and it should be stopped once confirmed on a complete blood count panel.</p>
          </list-item>
          <list-item>
            <p>GLP-1 receptor agonists should be avoided in gastroparesis or inflammatory bowel disorders. They should also be used cautiously in pregnancy. In animal embryo-fetal studies, these medications have shown evidence of pregnancy loss and adverse developmental outcomes when exposed to the maximum human recommended dosage. For other GLP-1 agonists, there is insufficient data to determine a drug-associated risk. Therefore,&#x000a0;these drugs should only be used when the benefit to the mother outweighs the risk to the fetus.</p>
          </list-item>
          <list-item>
            <p>The FDA has issued a warning regarding compounded semaglutide formulations. Compounding, which involves customizing medications, is not assessed by the FDA for safety or quality. Adverse events have been reported with compounded semaglutide, including cases with different salts. Three recent incidents involved incorrect administration for weight loss, resulting in severe symptoms. Patients obtained the medication from compounding pharmacies and a spa. Two patients self-administered doses&#x000a0;10 times higher than prescribed, leading to nausea, vomiting, and abdominal discomfort. One patient sought medical attention and improved with treatment. Patients also received syringes for self-administration without proper counseling. Compounded semaglutide lacks safety features, potentially causing dangerous overdoses. Incorrect syringes contribute to dosing variability and confusion. Strict labeling, dispensing, and counseling practices are crucial to reduce risks. Healthcare professionals should advocate for proper use to prevent severe adverse events and hospitalizations from dosing errors.<xref ref-type="bibr" rid="article-135573.r48">[48]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The FDA has further cautions against ileus related to semaglutide.&#x000a0;A recent study revealed that the utilization of GLP-1 agonists for weight loss, in contrast to bupropion-naltrexone, demonstrated a higher risk of pancreatitis, gastroparesis, and bowel obstruction.<xref ref-type="bibr" rid="article-135573.r49">[49]</xref><xref ref-type="bibr" rid="article-135573.r50">[50]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-135573.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Like other medications for type 2 diabetes, HbA1c should be checked every&#x000a0;3 months to monitor glycemic control, and blood glucose levels should be tested regularly. Patients may opt for a continuous glucose monitoring (CGM) device to examine their glycemic patterns to help make dosage changes.&#x000a0;There are reported cases of acute renal failure and renal insufficiency using exenatide and lixisenatide.</p>
        <p>Monitoring with renal function tests is recommended for patients taking these medications.&#x000a0;Patients taking GLP-1RA should be educated about the adverse effect profile and monitored for signs and symptoms of pancreatitis, gallbladder disease, and compressive symptoms of medullary thyroid cancer (eg, hoarseness or dysphagia). The FDA does not recommend monitoring calcitonin levels in patients taking GLP-1 analogs. Patients must receive yearly comprehensive eye exams as these agents, particularly semaglutide, may carry the risk of retinopathy associated with rapid glucose reduction.<xref ref-type="bibr" rid="article-135573.r51">[51]</xref>&#x000a0;If patients take GLP-1RAs, sulfonylureas, or insulin, there is an increased risk of hypoglycemia. Patients should be educated on the signs and symptoms of hypoglycemia and monitored periodically by their clinician.<xref ref-type="bibr" rid="article-135573.r52">[52]</xref></p>
      </sec>
      <sec id="article-135573.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>GLP-1 analog overdoses are few and far between. When they do occur, the symptoms include nausea, vomiting, and diarrhea, which have led to acute kidney injury likely secondary to dehydration. Excessive belching and abdominal pain have been reported as well. Serious complications like pancreatitis have not been experienced. There have been rare episodes of hypoglycemia that were corrected without long-term complications.<xref ref-type="bibr" rid="article-135573.r53">[53]</xref><xref ref-type="bibr" rid="article-135573.r54">[54]</xref></p>
        <p>Several case reports have shown that an overdose of GLP-1RAs mainly causes GI symptoms but either no or minimal hypoglycemia. These patients' symptoms are managed supportively according to their symptoms, with intravenous fluids to hydrate the patient and antiemetic medications to control nausea and vomiting.<xref ref-type="bibr" rid="article-135573.r55">[55]</xref><xref ref-type="bibr" rid="article-135573.r56">[56]</xref><xref ref-type="bibr" rid="article-135573.r57">[57]</xref></p>
      </sec>
      <sec id="article-135573.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>GLP-1 receptor agonists are an effective therapeutic choice for patients with type 2 diabetes and obesity. There is robust evidence from clinical trials and meta-analyses that show that GLP-1 receptor agonists reduce HbA1c levels, aid weight loss, and improve cardiovascular outcomes.<xref ref-type="bibr" rid="article-135573.r58">[58]</xref><xref ref-type="bibr" rid="article-135573.r59">[59]</xref><xref ref-type="bibr" rid="article-135573.r60">[60]</xref>&#x000a0;</p>
        <p>An interprofessional team comprised of a primary care physician, advanced practice practitioners, an endocrinologist, a pharmacist, a diabetes educator, nursing staff, and a dietician should be utilized when treating&#x000a0;type 2 diabetes and obese patients with a GLP-1 receptor agonist. Communication between these healthcare team members is the utmost priority. After reviewing the medication reconciliation&#x000a0;and laboratory results, they should use a patient-centered, holistic, interprofessional approach&#x000a0;regarding who&#x000a0;would benefit from a GLP-1 receptor agonist and work as a team in monitoring therapy to optimize patient outcomes.&#x000a0;</p>
        <p>GLP-1 receptor agonists may be limited due to their gastrointestinal side effects, subcutaneous injection route of administration, and cost. Pharmacists and clinicians should provide education&#x000a0;by demonstrating how to administer the drug properly and safely. This will help with compliance rates and adherence to the regimen and improve patient satisfaction. Pharmacists can contribute by counseling patients on adverse effects, monitoring parameters, appropriate usage, drug interactions, and therapy goals with GLP-1 analogs, and advising them to report any concerns to the office.&#x000a0;Pharmacists can also assist in navigating insurance coverage and out-of-pocket costs to arrive at the optimal agent and means of access, which can be facilitated by working with patient assistance programs, especially for patients for whom medication cost is a significant concern.&#x000a0;If a patient is experiencing gastrointestinal adverse effects following dose titration, the patient should be asked to verify the dose and the time of symptom onset.</p>
        <p>The healthcare team should institute routine follow-ups to monitor weight, kidney function, complete blood count, and blood glucose levels. A diabetic educator and a dietician can stress adding dietary changes and exercise while taking this medication for maximum treatment benefit.&#x000a0;Dieticians also&#x000a0;play a pivotal role by recommending smaller meals, eating more slowly, and avoiding fatty foods.&#x000a0;Cost can be a significant barrier as these medications are expensive. A&#x000a0;discussion should be initiated between patient and clinician to discuss&#x000a0;cost-effectiveness and provide financial assistance if needed.&#x000a0;A&#x000a0;comprehensive interprofessional healthcare team can improve outcomes and quality of life for patients with type 2 diabetes, as it can minimize adverse events, and clinicians should support these patients in reaching their personalized treatment goals to benefit their health.</p>
        <p>The comparison of GLP-1 receptor agonists has demonstrated that they all effectively reduce HbA1c levels in patients with type 2 diabetes. However, the agents vary within the class based on efficacy, safety, adverse effect profile, cardiovascular and renal effects, adherence, and persistence. When selecting a GLP-1 receptor agonist for a patient, a multidisciplinary healthcare team must consider all the available clinical evidence and individual patient factors like preference, cost, accessibility, and convenience.&#x000a0;Regarding the most significant reduction of HbA1c, long-acting agents seem superior to short-acting agents, with semaglutide having the most significant decrease. The lowest reduction was with exenatide extended-release. However,&#x000a0;the drug was still more effective at lowering the HbA1C than short-acting agents. For weight loss, the long-acting GLP-1 receptor agonists produced more significant weight loss than the short-acting formulations. Semaglutide was noted to cause the most significant weight reduction. The most gastrointestinal adverse effects were seen with short-acting agents and subcutaneous semaglutide, and the fewest side effects were seen with exenatide ER.</p>
        <p>Patient satisfaction, adherence, and persistence were seen more with long-acting agents, likely due to their less frequent dosing of once-weekly injections compared to once-daily or twice-daily of the short-acting agents. These comparative factors should be integral to the healthcare clinician&#x02019;s decision to choose a GLP-1 receptor agonist.</p>
      </sec>
      <sec id="article-135573.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=135573&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=135573">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/135573/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=135573">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-135573.s10">
        <title>References</title>
        <ref id="article-135573.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nachawi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Makin</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>The role of GLP-1 receptor agonists in managing type 2 diabetes.</article-title>
            <source>Cleve Clin J Med</source>
            <year>2022</year>
            <month>Aug</month>
            <day>01</day>
            <volume>89</volume>
            <issue>8</issue>
            <fpage>457</fpage>
            <page-range>457-464</page-range>
            <pub-id pub-id-type="pmid">35914933</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chudleigh</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Platts</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bain</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data.</article-title>
            <source>Diabetes Metab Syndr Obes</source>
            <year>2020</year>
            <volume>13</volume>
            <fpage>433</fpage>
            <page-range>433-438</page-range>
            <pub-id pub-id-type="pmid">32110076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <collab>American Diabetes Association</collab>
            <article-title>9. Pharmacologic Approaches to Glycemic Treatment: <italic>Standards of Medical Care in Diabetes-2021</italic>.</article-title>
            <source>Diabetes Care</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>44</volume>
            <issue>Suppl 1</issue>
            <fpage>S111</fpage>
            <page-range>S111-S124</page-range>
            <pub-id pub-id-type="pmid">33298420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>ElSayed</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Aleppo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Aroda</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Bannuru</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Bruemmer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Hilliard</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Kahan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khunti</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Leon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lyons</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Prahalad</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pratley</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Seley</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Stanton</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Gabbay</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>on behalf of the American Diabetes Association</surname>
              </name>
            </person-group>
            <article-title>9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023.</article-title>
            <source>Diabetes Care</source>
            <year>2023</year>
            <month>Jan</month>
            <day>01</day>
            <volume>46</volume>
            <issue>Suppl 1</issue>
            <fpage>S140</fpage>
            <page-range>S140-S157</page-range>
            <pub-id pub-id-type="pmid">36507650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilding</surname>
                <given-names>JPH</given-names>
              </name>
              <name>
                <surname>Batterham</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Calanna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Van Gaal</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Lingvay</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>McGowan</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Rosenstock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>MTD</given-names>
              </name>
              <name>
                <surname>Wadden</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Wharton</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yokote</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zeuthen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>RF</given-names>
              </name>
              <collab>STEP 1 Study Group</collab>
            </person-group>
            <article-title>Once-Weekly Semaglutide in Adults with Overweight or Obesity.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Mar</month>
            <day>18</day>
            <volume>384</volume>
            <issue>11</issue>
            <fpage>989</fpage>
            <page-range>989-1002</page-range>
            <pub-id pub-id-type="pmid">33567185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitchell</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Lyons</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Yiangou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grech</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Alimajstorovic</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Greig</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tsermoulas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brock</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mollan</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Sinclair</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial.</article-title>
            <source>Brain</source>
            <year>2023</year>
            <month>May</month>
            <day>02</day>
            <volume>146</volume>
            <issue>5</issue>
            <fpage>1821</fpage>
            <page-range>1821-1830</page-range>
            <pub-id pub-id-type="pmid">36907221</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Jun</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.</article-title>
            <source>Metabolism</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>63</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-19</page-range>
            <pub-id pub-id-type="pmid">24140094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garber</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability.</article-title>
            <source>Diabetes Care</source>
            <year>2011</year>
            <month>May</month>
            <volume>34 Suppl 2</volume>
            <issue>Suppl 2</issue>
            <fpage>S279</fpage>
            <page-range>S279-84</page-range>
            <pub-id pub-id-type="pmid">21525469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gentilella</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pechtner</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Corcos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Consoli</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?</article-title>
            <source>Diabetes Metab Res Rev</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>e3070</fpage>
            <pub-id pub-id-type="pmid">30156747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koliaki</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Doupis</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus.</article-title>
            <source>Diabetes Ther</source>
            <year>2011</year>
            <month>May</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>101</fpage>
            <page-range>101-21</page-range>
            <pub-id pub-id-type="pmid">22127804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xue</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials.</article-title>
            <source>Int J Clin Pract</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>70</volume>
            <issue>8</issue>
            <fpage>649</fpage>
            <page-range>649-56</page-range>
            <pub-id pub-id-type="pmid">27456750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Htike</surname>
                <given-names>ZZ</given-names>
              </name>
              <name>
                <surname>Zaccardi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Papamargaritis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Webb</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Khunti</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.</article-title>
            <source>Diabetes Obes Metab</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>524</fpage>
            <page-range>524-536</page-range>
            <pub-id pub-id-type="pmid">27981757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madsbad</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.</article-title>
            <source>Diabetes Obes Metab</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>317</fpage>
            <page-range>317-32</page-range>
            <pub-id pub-id-type="pmid">26511102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buse</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Rosenstock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sesti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Montanya</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Brett</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Zychma</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Blonde</surname>
                <given-names>L</given-names>
              </name>
              <collab>LEAD-6 Study Group</collab>
            </person-group>
            <article-title>Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).</article-title>
            <source>Lancet</source>
            <year>2009</year>
            <month>Jul</month>
            <day>04</day>
            <volume>374</volume>
            <issue>9683</issue>
            <fpage>39</fpage>
            <page-range>39-47</page-range>
            <pub-id pub-id-type="pmid">19515413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drucker</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Buse</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kendall</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Trautmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhuang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>L</given-names>
              </name>
              <collab>DURATION-1 Study Group</collab>
            </person-group>
            <article-title>Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.</article-title>
            <source>Lancet</source>
            <year>2008</year>
            <month>Oct</month>
            <day>04</day>
            <volume>372</volume>
            <issue>9645</issue>
            <fpage>1240</fpage>
            <page-range>1240-50</page-range>
            <pub-id pub-id-type="pmid">18782641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dungan</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Povedano</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Forst</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Atisso</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sealls</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Fahrbach</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.</article-title>
            <source>Lancet</source>
            <year>2014</year>
            <month>Oct</month>
            <day>11</day>
            <volume>384</volume>
            <issue>9951</issue>
            <fpage>1349</fpage>
            <page-range>1349-57</page-range>
            <pub-id pub-id-type="pmid">25018121</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morieri</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Rigato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Frison</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Simioni</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>D'Ambrosio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tadiotto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Paccagnella</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lapolla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Avogaro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fadini</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies.</article-title>
            <source>Metabolism</source>
            <year>2020</year>
            <month>May</month>
            <volume>106</volume>
            <fpage>154190</fpage>
            <pub-id pub-id-type="pmid">32109448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alatorre</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez Land&#x000f3;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Montejano</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Juneau</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mody</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Swindle</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.</article-title>
            <source>Diabetes Obes Metab</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>19</volume>
            <issue>7</issue>
            <fpage>953</fpage>
            <page-range>953-961</page-range>
            <pub-id pub-id-type="pmid">28181725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pratley</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Aroda</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Lingvay</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>L&#x000fc;demann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Andreassen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Navarria</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Viljoen</surname>
                <given-names>A</given-names>
              </name>
              <collab>SUSTAIN 7 investigators</collab>
            </person-group>
            <article-title>Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.</article-title>
            <source>Lancet Diabetes Endocrinol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>275</fpage>
            <page-range>275-286</page-range>
            <pub-id pub-id-type="pmid">29397376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sheahan</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Wahlberg</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>An overview of GLP-1 agonists and recent cardiovascular outcomes trials.</article-title>
            <source>Postgrad Med J</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>96</volume>
            <issue>1133</issue>
            <fpage>156</fpage>
            <page-range>156-161</page-range>
            <pub-id pub-id-type="pmid">31801807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Husain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bain</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Holst</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Mark</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lingvay</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials.</article-title>
            <source>Cardiovasc Diabetol</source>
            <year>2020</year>
            <month>Sep</month>
            <day>30</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>156</fpage>
            <pub-id pub-id-type="pmid">32998732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marx</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Husain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lehrke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sattar</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes.</article-title>
            <source>Circulation</source>
            <year>2022</year>
            <month>Dec</month>
            <day>13</day>
            <volume>146</volume>
            <issue>24</issue>
            <fpage>1882</fpage>
            <page-range>1882-1894</page-range>
            <pub-id pub-id-type="pmid">36508493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tuttle</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Lakshmanan</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Rayner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Busch</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Zimmermann</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Woodward</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Botros</surname>
                <given-names>FT</given-names>
              </name>
            </person-group>
            <article-title>Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.</article-title>
            <source>Lancet Diabetes Endocrinol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>6</volume>
            <issue>8</issue>
            <fpage>605</fpage>
            <page-range>605-617</page-range>
            <pub-id pub-id-type="pmid">29910024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Husain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Birkenfeld</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Donsmark</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dungan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Eliaschewitz</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Franco</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Jeppesen</surname>
                <given-names>OK</given-names>
              </name>
              <name>
                <surname>Lingvay</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mosenzon</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Tack</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Thomsen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vilsb&#x000f8;ll</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Warren</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Bain</surname>
                <given-names>SC</given-names>
              </name>
              <collab>PIONEER 6 Investigators</collab>
            </person-group>
            <article-title>Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Aug</month>
            <day>29</day>
            <volume>381</volume>
            <issue>9</issue>
            <fpage>841</fpage>
            <page-range>841-851</page-range>
            <pub-id pub-id-type="pmid">31185157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trujillo</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Nuffer</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>GLP-1 receptor agonists: an updated review of head-to-head clinical studies.</article-title>
            <source>Ther Adv Endocrinol Metab</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>2042018821997320</fpage>
            <pub-id pub-id-type="pmid">33767808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nauck</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Quast</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Wefers</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Meier</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.</article-title>
            <source>Mol Metab</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>46</volume>
            <fpage>101102</fpage>
            <pub-id pub-id-type="pmid">33068776</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r27">
          <label>27</label>
          <element-citation publication-type="book">
            <chapter-title>Glucagon-Like Peptide-1 (GLP-1) Analogues</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2019</year>
            <month>4</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">31643819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kup&#x0010d;ov&#x000e1;</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Arold</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Roepstorff</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>H&#x000f8;jbjerre</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haahr</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment.</article-title>
            <source>Clin Drug Investig</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>127</fpage>
            <page-range>127-33</page-range>
            <pub-id pub-id-type="pmid">24277680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r29">
          <label>29</label>
          <element-citation publication-type="book">
            <chapter-title>Exenatide</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2019</year>
            <month>4</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">31643976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r30">
          <label>30</label>
          <element-citation publication-type="book">
            <chapter-title>Semaglutide</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2019</year>
            <month>4</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">31643889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r31">
          <label>31</label>
          <element-citation publication-type="book">
            <chapter-title>Tirzepatide</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2022</year>
            <month>6</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">35780672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Boer</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Khunti</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sadusky</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tuttle</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Neumiller</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Rhee</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Rosas</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Rossing</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bakris</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).</article-title>
            <source>Diabetes Care</source>
            <year>2022</year>
            <month>Dec</month>
            <day>01</day>
            <volume>45</volume>
            <issue>12</issue>
            <fpage>3075</fpage>
            <page-range>3075-3090</page-range>
            <pub-id pub-id-type="pmid">36189689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Urquhart</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>FDA new drug approvals in Q3 2019.</article-title>
            <source>Nat Rev Drug Discov</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>18</volume>
            <issue>11</issue>
            <fpage>816</fpage>
            <pub-id pub-id-type="pmid">31673140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thieu</surname>
                <given-names>VT</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kennedy-Martin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Boye</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Garcia-Perez</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Patient preferences for glucagon-like peptide 1 receptor-agonist treatment attributes.</article-title>
            <source>Patient Prefer Adherence</source>
            <year>2019</year>
            <volume>13</volume>
            <fpage>561</fpage>
            <page-range>561-576</page-range>
            <pub-id pub-id-type="pmid">31114170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boye</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mody</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Konig</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gelhorn</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Patients' preferences for once-daily oral versus once-weekly injectable diabetes medications: The REVISE study.</article-title>
            <source>Diabetes Obes Metab</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>508</fpage>
            <page-range>508-519</page-range>
            <pub-id pub-id-type="pmid">33140575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Trujillo</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Basal Insulin Use With GLP-1 Receptor Agonists.</article-title>
            <source>Diabetes Spectr</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>152</fpage>
            <page-range>152-60</page-range>
            <pub-id pub-id-type="pmid">27574369</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jensterle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rizzo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haluz&#x000ed;k</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jane&#x0017e;</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review.</article-title>
            <source>Adv Ther</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>39</volume>
            <issue>6</issue>
            <fpage>2452</fpage>
            <page-range>2452-2467</page-range>
            <pub-id pub-id-type="pmid">35503498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gourgari</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Huerta-Saenz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tonyushkina</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Rosolowsky</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Guttmann-Bauman</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Use of glucagon-like peptide-1 receptor agonists for pediatric patients with obesity and diabetes: The providers' perspectives.</article-title>
            <source>Pediatr Diabetes</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>22</volume>
            <issue>6</issue>
            <fpage>872</fpage>
            <page-range>872-875</page-range>
            <pub-id pub-id-type="pmid">34018306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hampl</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Hassink</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Skinner</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Barlow</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Bolling</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Avila Edwards</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Eneli</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hamre</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lunsford</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mendonca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Michalsky</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Mirza</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ochoa</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Sharifi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Staiano</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Weedn</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Flinn</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Lindros</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Okechukwu</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity.</article-title>
            <source>Pediatrics</source>
            <year>2023</year>
            <month>Feb</month>
            <day>01</day>
            <volume>151</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">36622115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karagiannis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tsapas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Athanasiadou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Avgerinos</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Liakos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Matthews</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Bekiari</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis.</article-title>
            <source>Diabetes Res Clin Pract</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>174</volume>
            <fpage>108737</fpage>
            <pub-id pub-id-type="pmid">33705820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gerstein</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Colhoun</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Dagenais</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lakshmanan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pais</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Probstfield</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Riesmeyer</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Riddle</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Ryd&#x000e9;n</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Xavier</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Atisso</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Dyal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rao-Melacini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Avezum</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Basile</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Conget</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cushman</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Franek</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hancu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hanefeld</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Holt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jansky</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Keltai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lanas</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Leiter</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Lopez-Jaramillo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cardona Munoz</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Pirags</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pogosova</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Raubenheimer</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Sheu</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Temelkova-Kurktschiev</surname>
                <given-names>T</given-names>
              </name>
              <collab>REWIND Investigators</collab>
            </person-group>
            <article-title>Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.</article-title>
            <source>Lancet</source>
            <year>2019</year>
            <month>Jul</month>
            <day>13</day>
            <volume>394</volume>
            <issue>10193</issue>
            <fpage>121</fpage>
            <page-range>121-130</page-range>
            <pub-id pub-id-type="pmid">31189511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Umana</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Exacerbation of atrial fibrillation related to dulaglutide use.</article-title>
            <source>Clin Case Rep</source>
            <year>2021</year>
            <month>May</month>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>e04223</fpage>
            <pub-id pub-id-type="pmid">34026191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ornelas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Caiado</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lopes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pereira Dos Santos</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Pereira Barbosa</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Anaphylaxis to Long-Acting Release Exenatide.</article-title>
            <source>J Investig Allergol Clin Immunol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>332</fpage>
            <page-range>332-334</page-range>
            <pub-id pub-id-type="pmid">30350785</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pradhan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Montastruc</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rousseau</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Patorno</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Azoulay</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Exendin-based glucagon-like peptide-1 receptor agonists and anaphylactic reactions: a pharmacovigilance analysis.</article-title>
            <source>Lancet Diabetes Endocrinol</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-14</page-range>
            <pub-id pub-id-type="pmid">31806579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Trujillo</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Association of pancreatitis with glucagon-like peptide-1 agonist use.</article-title>
            <source>Ann Pharmacother</source>
            <year>2010</year>
            <month>May</month>
            <volume>44</volume>
            <issue>5</issue>
            <fpage>904</fpage>
            <page-range>904-9</page-range>
            <pub-id pub-id-type="pmid">20371755</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bjerre Knudsen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Madsen</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Almholt</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>de Boer</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Drucker</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Gotfredsen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Egerod</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Hegelund</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Moses</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>M&#x000f8;lck</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Nowak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Solberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Thi</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Zdravkovic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moerch</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.</article-title>
            <source>Endocrinology</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>151</volume>
            <issue>4</issue>
            <fpage>1473</fpage>
            <page-range>1473-86</page-range>
            <pub-id pub-id-type="pmid">20203154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prasad-Reddy</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond.</article-title>
            <source>Drugs Context</source>
            <year>2015</year>
            <volume>4</volume>
            <fpage>212283</fpage>
            <pub-id pub-id-type="pmid">26213556</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lambson</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Flegal</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Administration errors of compounded semaglutide reported to a poison control center-Case series.</article-title>
            <source>J Am Pharm Assoc (2003)</source>
            <year>2023</year>
            <season>Sep-Oct</season>
            <volume>63</volume>
            <issue>5</issue>
            <fpage>1643</fpage>
            <page-range>1643-1645</page-range>
            <pub-id pub-id-type="pmid">37392810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gorgojo-Mart&#x000ed;nez</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Mezquita-Raya</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Carretero-G&#x000f3;mez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Castro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cebri&#x000e1;n-Cuenca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de Torres-S&#x000e1;nchez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-de-Lucas</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>N&#x000fa;&#x000f1;ez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Obaya</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Soler</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>G&#x000f3;rriz</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Rubio-Herrera</surname>
                <given-names>M&#x000c1;</given-names>
              </name>
            </person-group>
            <article-title>Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus.</article-title>
            <source>J Clin Med</source>
            <year>2022</year>
            <month>Dec</month>
            <day>24</day>
            <volume>12</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">36614945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sodhi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rezaeianzadeh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kezouh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Etminan</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss.</article-title>
            <source>JAMA</source>
            <year>2023</year>
            <month>Nov</month>
            <day>14</day>
            <volume>330</volume>
            <issue>18</issue>
            <fpage>1795</fpage>
            <page-range>1795-1797</page-range>
            <pub-id pub-id-type="pmid">37796527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marso</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Bain</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Consoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eliaschewitz</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>J&#x000f3;dar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Leiter</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Lingvay</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Rosenstock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Seufert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Warren</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Holst</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Pettersson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vilsb&#x000f8;ll</surname>
                <given-names>T</given-names>
              </name>
              <collab>SUSTAIN-6 Investigators</collab>
            </person-group>
            <article-title>Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Nov</month>
            <day>10</day>
            <volume>375</volume>
            <issue>19</issue>
            <fpage>1834</fpage>
            <page-range>1834-1844</page-range>
            <pub-id pub-id-type="pmid">27633186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frias</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Safety of Once-weekly Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes.</article-title>
            <source>J Fam Pract</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>67</volume>
            <issue>6 suppl</issue>
            <fpage>S25</fpage>
            <page-range>S25-S34</page-range>
            <pub-id pub-id-type="pmid">29912998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Filippatos</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Panagiotopoulou</surname>
                <given-names>TV</given-names>
              </name>
              <name>
                <surname>Elisaf</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Adverse Effects of GLP-1 Receptor Agonists.</article-title>
            <source>Rev Diabet Stud</source>
            <year>2014</year>
            <season>Fall-Winter</season>
            <volume>11</volume>
            <issue>3-4</issue>
            <fpage>202</fpage>
            <page-range>202-30</page-range>
            <pub-id pub-id-type="pmid">26177483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elmehdawi</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Elbarsha</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>An accidental liraglutide overdose: case report.</article-title>
            <source>Libyan J Med</source>
            <year>2014</year>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>23055</fpage>
            <pub-id pub-id-type="pmid">24461534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakanishi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hirose</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fujitani</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Watada</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Attempted suicide with liraglutide overdose did not induce hypoglycemia.</article-title>
            <source>Diabetes Res Clin Pract</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>99</volume>
            <issue>1</issue>
            <fpage>e3</fpage>
            <page-range>e3-4</page-range>
            <pub-id pub-id-type="pmid">23149376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madsen</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Christiansen</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>[A 45-fold liraglutide overdose did not cause hypoglycaemia].</article-title>
            <source>Ugeskr Laeger</source>
            <year>2015</year>
            <month>Jan</month>
            <day>26</day>
            <volume>177</volume>
            <issue>5</issue>
            <fpage>V11140595</fpage>
            <pub-id pub-id-type="pmid">25650514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nafisah</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Almatrafi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Al-Mulhim</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Liraglutide overdose: A case report and an updated review.</article-title>
            <source>Turk J Emerg Med</source>
            <year>2020</year>
            <season>Jan-Mar</season>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>46</fpage>
            <page-range>46-49</page-range>
            <pub-id pub-id-type="pmid">32355902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Potts</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Brady</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Khunti</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bodicoat</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.</article-title>
            <source>PLoS One</source>
            <year>2015</year>
            <volume>10</volume>
            <issue>6</issue>
            <fpage>e0126769</fpage>
            <pub-id pub-id-type="pmid">26121478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bethel</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Merrill</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lokhnygina</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Buse</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Mentz</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Pagidipati</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Gustavson</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Iqbal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Maggioni</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>&#x000d6;hman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Poulter</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Ramachandran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zinman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Holman</surname>
                <given-names>RR</given-names>
              </name>
              <collab>EXSCEL Study Group</collab>
            </person-group>
            <article-title>Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.</article-title>
            <source>Lancet Diabetes Endocrinol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>105</fpage>
            <page-range>105-113</page-range>
            <pub-id pub-id-type="pmid">29221659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135573.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Retnakaran</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zinman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>CK</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials.</article-title>
            <source>Diabetes Obes Metab</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>20 Suppl 1</volume>
            <fpage>68</fpage>
            <page-range>68-76</page-range>
            <pub-id pub-id-type="pmid">29364587</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
